DAX6.682-1,6%  Dow12.8910,1%  Euro1,3177-0,8% 
ESt502.483-1,6%  Nas2.9270,4%  Öl116,8-1,6% 
TDax771,8-0,2%  Nikkei8.947-0,6%  Gold1.707-1,4% 
Home > Aktien > Incyte Aktie > Nachrichten zu Incyte

Incyte Aktie [WKN: 896133 / ISIN: US45337C1027]

Kurse + Charts + RealtimeNews + AnalysenFundamentalUnternehmenzugeh. WertpapiereAktion
Kurs + ChartChart (groß)News + AdhocBilanz/GuVTermineZertifikateDepot
Times + SalesChart-AnalyseAnalysenDividende/HVProfilOptionsscheineWatchlist
BörsenplätzeChartvergleichKursziele InsidertradesKnock-outsmyfinanzen
OrderbuchRealtime StuttgartRSS FeedAnalyseim ForumFondsSenden
HistorischRealtime Push  IR-DatenAnleihen
handeln

Hinweis

Auf dieser Seite finden Sie ALLE Nachrichten zur Incyte Corp.. Links ausgesuchte Top-Nachrichten, rechts weitere Meldungen.

Newssuche

 GO 

ALLE Nachrichten zur Incyte Corp.

25.02.10Incyte to Present at the Cowen and Company 30th Annual Health Care Conference
18.02.10Incyte Reports 2009 Financial Results; Strengthens Balance Sheet; Provides 2010 Financial Guidance
09.02.10Incyte to Report 2009 Financial Results and 2010 Financial Guidance and Provide Update on Drug Discovery & Development Programs on February 18
28.01.10Incyte Announces Redemption of Its 3½% Convertible Senior Notes Due 2011 and Its 3½% Convertible Subordinated Notes Due 2011
05.01.10Incyte to Present at the 28th Annual JPMorgan Healthcare Conference
22.12.09Ausblick: Stärkere Eröffnung erwartet; US-BIP steht an
21.12.09Wall Street Schluss: Deutliche Aufschläge, Übernahmen heben Stimmung
21.12.09Wall Street Update: Weiterhin fest, Übernahmen heben Stimmung
21.12.09Eli Lilly kooperiert mit Incyte
21.12.09Incyte to Host Conference Call to Discuss Its Collaboration with Lilly for the Development and Commercialization of Oral Anti-Inflammatory and Autoimmune Therapies
02.12.09Incyte to Host Webcast at 51st American Hematology Annual Meeting
25.11.09Incyte Announces Major Collaboration and License Agreement for Two Hematology-Oncology Programs
05.11.09Incyte Reports Third Quarter 2009 Financial Results and Provides Update on Drug Development Programs
20.10.09Incyte to Report Third Quarter 2009 Financial Results and Provide Update on Drug Discovery & Development Programs on November 5
30.09.09Incyte to Present at the Fourth Annual JMP Securities Healthcare Focus Conference
30.09.09Incyte Completes Offering of Convertible Senior Notes
30.09.09Incyte Announces Closing of Public Offering of Common Stock
24.09.09Incyte Prices $350 Million Convertible Senior Notes Offering
24.09.09Incyte Announces Pricing of Public Offering of 18,000,000 Shares of Common Stock
22.09.09Incyte Announces Proposed Public Offering of 18,000,000 Shares of Common Stock
22.09.09Incyte Announces Proposed Offering of $250 Million Convertible Senior Notes
21.09.09Incyte Announces Positive Top-Line Phase IIb Results for Topical INCB18424 in Psoriasis
03.09.09Incyte to Present at Upcoming Investor Conferences
30.07.09Incyte Reports Second Quarter 2009 Financial Results and Provides Update on Drug Development Programs
21.07.09Incyte Reaches Agreement with FDA on a Special Protocol Assessment for INCB18424 in Myelofibrosis
15.07.09Incyte to Report Second Quarter 2009 Financial Results and Provide Update on Drug Discovery & Development Programs on July 30
28.05.09Incyte Provides Update on Special Protocol Assessment for INCB18424 as a New Treatment for Myelofibrosis
26.05.09Incyte to Present at Goldman Sachs 30th Annual Global Healthcare Conference
07.05.09Incyte Reports First Quarter 2009 Financial Results and Provides Update on Drug Development Programs
21.04.09Incyte to Report First Quarter 2009 Financial Results and Provide Update on Drug Discovery & Development Programs on May 7
24.03.09Incyte to Present at Citi's 4th Annual Biotech Day Conference
09.03.09Incyte to Present at Cowen and Company 29th Annual Health Care Conference
18.02.09Incyte Reports Fourth Quarter and Year-End 2008 Financial Results; Announces 2009 Financial Guidance
04.02.09Incyte to Report 2008 Financial Results and 2009 Financial Guidance and Provide Update on Drug Discovery & Development Programs on February 18
13.01.09Incyte to Announce 2009 Objectives at JPMorgan Healthcare Conference; JAK Inhibitor Program Highest Priority
05.01.09Incyte to Present at the 27th Annual JPMorgan Healthcare Conference
06.12.08Incyte's Selective JAK1 / 2 Inhibitor, INCB18424, Demonstrates Rapid and Durable Clinical Benefits in Myelofibrosis Patients
20.11.08Incyte to Present at the 20th Annual Piper Jaffray Health Care Conference
06.11.08Incyte Reports Progress in Multiple Clinical Programs Announces Third Quarter Financial Results
30.10.08Incyte to Present at 2008 DB-Biotech Boston Confab

Anzeige

ANZEIGE

 
Wie bewerten Sie diese Seite?
schlecht sehr gut
Aktien Prime Standard: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z DAX MDAX Dow Jones EuroStoxx

Kontakt - Impressum - Werben - Presse

finanzen.net als Startseite - Sitemap - Arbeiten bei finanzen.net - RSS-Feeds - Datenschutz - Disclaimer - Nutzungsbedingungen


Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Telekurs. Verzögerung Deutsche Börse: 15 Min., Nasdaq, NYSE: 20 Min. © 1999-2012 finanzen.net GmbH

News Aktien Kurslisten Analysen Devisen Dollarkurs Fonds Zertifikate Optionsscheine Anleihen Rohstoffe Aktien kaufen Portfolio Links Aktien China Währungsrechner Gold kaufen CFD Aktienkurse Ölpreis Leitzins Heizölpreis IPO Börsenkurse Lexikon